Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets

Cancer Gene Therapy volume 23, pages 48–53 (2016)Cite this article

Subjects

Abstract

Cholangiocarcinoma (CCA) continues to harbor a difficult prognosis and it is difficult to diagnose in its early stages. The molecular mechanisms of CCA oncogenesis and progression are poorly understood. This study aimed to identify candidate biomarkers for CCA. Integrated analysis of microarray data sets was performed to identify differentially expressed genes (DEGs) between CCA and normal tissues. Gene Ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were then performed to identify the functions of DEGs. Furthermore, the protein–protein interaction (PPI) network of DEGs was constructed. The expressions of DEGs were validated in human CCA tissues by qRT-PCR. A set of 712 DEGs were identified in CCA compared with normal tissues, including 306 upregulated and 406 downregulated DEGs. It can be shown from the KEGG pathway analysis that some pathways may have important roles in pathology of CCA, including peroxisome proliferator-activated receptor signaling pathway, bile secretion, cell cycle, fat digestion and absorption. PPI network indicated that the significant hub proteins were PKM, SPP1 and TPM1. The abnormally overexpression PKM, SPP1 and TPM1 were closely related to oncogenesis and progression of CCA. PKM, SPP1, TPM1, COL1A1 and COL1A2 may serve as candidate biomarkers for diagnosis and prognosis of CCA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM . Biliary tract cancers. New Engl J Med 1999; 341: 1368–1378.

    Article  CAS  Google Scholar 

  2. Wu T, Han C, Lunz JG 3rd, Michalopoulos G, Shelhamer JH, Demetris AJ . Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology 2002; 36: 363–373.

    Article  CAS  Google Scholar 

  3. Shaib YH, Davila JA, McGlynn K, El-Serag HB . Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472–477.

    Article  Google Scholar 

  4. Patel T . Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.

    Article  Google Scholar 

  5. Chang KY, Chang JY, Yen Y . Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 2009; 7: 423–427.

    Article  Google Scholar 

  6. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463–473.

    Article  CAS  Google Scholar 

  7. Patel T . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353–1357.

    Article  CAS  Google Scholar 

  8. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995; 109: 1612–1617.

    Article  CAS  Google Scholar 

  9. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y . Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999; 35: 230–240.

    Article  CAS  Google Scholar 

  10. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706–712.

    Article  CAS  Google Scholar 

  11. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006; 116: 1843–1852.

    Article  CAS  Google Scholar 

  12. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE . ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002; 36: 439–450.

    Article  CAS  Google Scholar 

  13. Sugawara H, Yasoshima M, Katayanagi K, Kono N, Watanabe Y, Harada K et al. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 1998; 33: 145–153.

    Article  CAS  Google Scholar 

  14. Seol MA, Chu IS, Lee MJ, Yu GR, Cui XD, Cho BH et al. Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma. BMC Cancer 2011; 11: 78.

    Article  CAS  Google Scholar 

  15. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 2013; 41: D991–D995.

    Article  CAS  Google Scholar 

  16. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 2007; 8: R183.

    Article  Google Scholar 

  17. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25–29.

    Article  CAS  Google Scholar 

  18. Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27–30.

    Article  CAS  Google Scholar 

  19. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B . STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 2003; 31: 258–261.

    Article  CAS  Google Scholar 

  20. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41: D808–D815.

    Article  CAS  Google Scholar 

  21. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T . Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011; 27: 431–432.

    Article  CAS  Google Scholar 

  22. Ikenaga N, Liu SB, Sverdlov DY, Yoshida S, Nasser I, Ke Q et al. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol 2015; 185: 325–334.

    Article  CAS  Google Scholar 

  23. Yeh CN, Weng WH, Lenka G, Tsao LC, Chiang KC, Pang ST et al. cDNA microarray pro fi ling of rat cholangiocarcinoma induced by thioacetamide. Mol Med Rep 2013; 8: 350–360.

    Article  Google Scholar 

  24. Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K et al. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 2014; 5: 8202–8210.

    Article  Google Scholar 

  25. Yang W, Wang X, Zheng W, Li K, Liu H, Sun Y . Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma. Int J Oncol 2013; 42: 690–698.

    Article  CAS  Google Scholar 

  26. Verma A, Matta A, Shukla NK, Deo SV, Gupta SD, Ralhan R . Clinical significance of mannose-binding lectin-associated serine protease-2 expression in esophageal squamous cell carcinoma. Int J Cancer 2006; 118: 2930–2935.

    Article  CAS  Google Scholar 

  27. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685–696.

    Article  CAS  Google Scholar 

  28. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G . Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 1997; 17: 3153–3156.

    CAS  PubMed  Google Scholar 

  29. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD et al. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077–5082.

    CAS  PubMed  Google Scholar 

  30. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH et al. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 2012; 18: 4037–4043.

    Article  CAS  Google Scholar 

  31. Zhan C, Shi Y, Lu C, Wang Q . Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer. Dis Esophagus 2013; 26: 746–753.

    CAS  PubMed  Google Scholar 

  32. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K et al. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001; 91: 67–75.

    Article  CAS  Google Scholar 

  33. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98: 119–127.

    Article  CAS  Google Scholar 

  34. Hass HG, Nehls O, Jobst J, Frilling A, Vogel U, Kaiser S . Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol 2008; 14: 2501–2510.

    Article  CAS  Google Scholar 

  35. Choi C, Kim D, Kim S, Jeong S, Song E, Helfman DM . From skeletal muscle to cancer: insights learned elucidating the function of tropomyosin. J Struct Biol 2012; 177: 63–69.

    Article  CAS  Google Scholar 

  36. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003; 22: 6194–6203.

    Article  CAS  Google Scholar 

  37. Pawlak G, McGarvey TW, Nguyen TB, Tomaszewski JE, Puthiyaveettil R, Malkowicz SB et al. Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. Int J Cancer 2004; 110: 368–373.

    Article  CAS  Google Scholar 

  38. Yager ML, Hughes JA, Lovicu FJ, Gunning PW, Weinberger RP, O'Neill GM . Functional analysis of the actin-binding protein, tropomyosin 1, in neuroblastoma. Br J Cancer 2003; 89: 860–863.

    Article  CAS  Google Scholar 

  39. Bharadwaj S, Prasad GL . Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. Cancer Lett 2002; 183: 205–213.

    Article  CAS  Google Scholar 

  40. Schevzov G, Whittaker SP, Fath T, Lin JJ, Gunning PW . Tropomyosin isoforms and reagents. Bioarchitecture 2011; 1: 135–164.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from Yantai Science and Technology Development Plan (No. 2014WS020).

Author information

Author notes

  1. Q-X Huang and J-Y Cui: These authors contributed equally to the work.

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Yantai, Shan Dong Province, China

    Q-X Huang, X-M Jia, F-L Huang & L-X Jiang

  2. Department of General Surgery, Qingdao Municipal Hospital, Qingdao, Shan Dong Province, China

    J-Y Cui & H Ma

Authors
  1. Q-X Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J-Y Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X-M Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F-L Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L-X Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to J-Y Cui or L-X Jiang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Cancer Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, QX., Cui, JY., Ma, H. et al. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets. Cancer Gene Ther 23, 48–53 (2016). https://doi.org/10.1038/cgt.2015.66

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2015.66

This article is cited by

Search

Advanced search

Quick links